FARMACOLOGIA DEL SISTEMA INMUNE

More documents

Recommendations

Info

B7.1 and B7.2: What’s the difference? Expression: Primarily limited to APCs B7.1 is absent from unstimulated cells. B7.2 is constitutively expressed at low levels on unstimulated DCs and blood monocytes. Activation of APCs induces B7 expression. In general, the induction of B7.2 expression follows faster kinetics and usually reaches higher values than does B7.1 induction. In vivo, anti B7.2 mAb was shown to be more efficient than anti-B7.1 mAb to block the expansion of Ag-specific T cells. B7.1 KO vs B7.2 KO: When immunized intravenously without adjuvant, B7.2-deficient mice failed to form germinal centers, whereas B7.1-deficient mice gave Ab responses comparable with wild-type mice. B7.2 is probably the major initial ligand for CD28 while B7.1 which is expressed later sustains T cell activation.
Mab ANTI CTLA-4 (Ipililumab)
Page 1 and 2: FARMACOLOGIA DEL SISTEMA INMUNE Inm
Page 5 and 6: INMUNOSUPRESIÓN
Page 7 and 8: Jean Francois Borel
Page 9: Estructura de la ciclosporina
Page 13 and 14: The Two-Signal Model of T-cell Acti
Page 15 and 16: Marc Jenkins and Ronald Schwartz in
Page 17 and 18: Cells with this costimulatory funct
Page 19 and 20: In vitro T cell responses in CD28 K
Page 21 and 22: Major effects of CD28-mediated cost
Page 23 and 24: The new concept (based on the visua
Page 25: Thus, in addition to a role in init
Page 29 and 30: mAb against CTLA-4 was found to co
Page 31 and 32: Phenotype of CTLA-4 KO mice This is
Page 33 and 34: CTLA-4 is not readily detectable in
Page 35 and 36: The threshold model:When B7 levels
Page 37 and 38: There are two scenarios in which CT
Page 39 and 40: The attenuation model:When B7 level
Page 41 and 42: CTLA-4 would prevent this high-affi
Page 43 and 44: T cell-mediated immunotherapy repre

FARMACOLOGIA DEL SISTEMA INMUNE

Create successful ePaper yourself

Delete template?

Save as template?